SCHEMBL252561

SCHEMBL252561

CC(C)[C@H](O)[C@@H](O)c1c(Cl)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
PNMT P11086 1/20 0.36
LMNA P02545 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GLA P06280 1/20 0.35
TSHR P16473 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ADRB1 P08588 2/20 0.34
AOC3 Q16853 1/20 0.34
ADRB2 P07550 1/20 0.34
CYP2A6 P11509 1/20 0.33
MIF P14174 1/20 0.33
HTR2A P28223 1/20 0.33
ADRA1A P35348 1/20 0.33
HTR2B P41595 1/20 0.33
DRD2 P14416 2/20 0.33
DRD3 P35462 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252562 1.00 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL252314 1.00 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL252877 1.00 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL252878 1.00 CYP1A2 (0.36) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL18567607 0.88 GAA (0.33) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL19254449 0.88 GAA (0.33) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL16071369 0.88 GAA (0.33) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL19415506 0.82 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL20604401 0.82 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL20604426 0.82 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6NFKB1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
EP-2968210-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY BIO PHARM SOLUTIONS CO LTD (KR) 2024-09-11 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
CN-111419830-B Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes 比皮艾思药物研发有限公司 2024-01-30 CN disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
CN-115996905-A Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases 生物药品解决方案有限公司 2023-04-21 CN disclosed
CN-109939092-B Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome 比皮艾思药物研发有限公司 2022-03-22 CN disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME CPT1B, MYLK, PYGM CYP1A2 789/4885CYP3A4 211/4885CYP2D6 841/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT CYP1A2 4573/4885CYP3A4 4695/4885CYP2D6 4798/4885
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES CPS1, BCHE, ACHE CYP1A2 60/4885CYP3A4 11/4885CYP2D6 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.